Owkin

Company profile

About Owkin

Owkin is building what it calls Biological Artificial Superintelligence—an autonomous AI scientist designed to automate biopharma research and development. The company's vision is a world where R&D is automated and research is directly connected to care, addressing the profound complexity of biology that exceeds the limits of human intelligence alone. Owkin's flagship product, K Pro, is an AI agent that connects research and care, continuously learning from real-world data, user feedback, and clinical validation. K Pro enables pharma companies to make data-driven decisions across the entire drug development pipeline—from target discovery and biomarker validation to patient stratification and clinical trial design. The platform is trained and validated on MOSAIC, Owkin's proprietary multimodal patient data network spanning multiple therapeutic areas and healthcare institutions across Europe and North America. This network provides deeply curated clinical data alongside spatial transcriptomics, single-cell RNA, bulk RNA, whole exome sequencing, and H&E pathology images. Owkin's AI is refined through wet lab infrastructure and a global network of leading oncologists and biologists, with findings fed back to continuously improve the AI scientist. The company has published over 70 papers in high-impact journals and partners with leading academic medical centers, pharma companies including Sanofi, and consulting firms. Owkin has also incubated Bioptimus (building foundation models for biology), spun out Waiv (AI-powered precision diagnostics), and sponsors clinical trials through its affiliate Epkin. With offices in Paris, London, New York, Geneva, Nantes, and Boston, Owkin is positioning itself at the forefront of agentic AI for drug discovery and development.

Company description · Owkin official website